Amgen Inc. $AMGN Stake Increased by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 62.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,555 shares of the medical research company’s stock after buying an additional 2,904 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Amgen were worth $2,132,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Brighton Jones LLC grew its stake in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after purchasing an additional 114 shares during the period. Janney Capital Management LLC grew its position in Amgen by 27.6% during the second quarter. Janney Capital Management LLC now owns 1,037 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 224 shares in the last quarter. Union Bancaire Privee UBP SA increased its stake in Amgen by 94.4% in the 2nd quarter. Union Bancaire Privee UBP SA now owns 4,432 shares of the medical research company’s stock valued at $1,237,000 after buying an additional 2,152 shares during the period. Finally, Alley Investment Management Company LLC increased its stake in Amgen by 1.1% in the 2nd quarter. Alley Investment Management Company LLC now owns 25,052 shares of the medical research company’s stock valued at $6,995,000 after buying an additional 280 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Amgen

In related news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares in the company, valued at $14,120,924.09. This trade represents a 14.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 10,908 shares of company stock worth $3,674,966. 0.69% of the stock is owned by insiders.

Amgen Price Performance

NASDAQ AMGN opened at $342.22 on Thursday. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $353.25. The stock’s 50-day moving average is $332.38 and its two-hundred day moving average is $308.67. The firm has a market cap of $184.28 billion, a P/E ratio of 26.45, a price-to-earnings-growth ratio of 3.11 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.01 by $0.63. The company had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The firm’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is 73.57%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on AMGN shares. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Wells Fargo & Company increased their price objective on Amgen from $300.00 to $325.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. UBS Group boosted their target price on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Monday. Morgan Stanley dropped their target price on Amgen from $329.00 to $304.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Finally, Guggenheim lifted their price target on Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen has an average rating of “Moderate Buy” and an average price target of $339.71.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.